Equities research analysts predict that IDEXX Laboratories, Inc. (NASDAQ:IDXX) will report earnings of $0.91 per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for IDEXX Laboratories’ earnings, with the highest EPS estimate coming in at $0.93 and the lowest estimate coming in at $0.90. IDEXX Laboratories reported earnings of $0.98 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 7.1%. The business is expected to announce its next earnings results on Friday, February 7th.
According to Zacks, analysts expect that IDEXX Laboratories will report full-year earnings of $4.76 per share for the current year, with EPS estimates ranging from $4.75 to $4.78. For the next financial year, analysts expect that the business will report earnings of $5.42 per share, with EPS estimates ranging from $5.37 to $5.45. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, October 31st. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.14 by $0.10. The company had revenue of $605.30 million for the quarter, compared to the consensus estimate of $597.09 million. IDEXX Laboratories had a return on equity of 405.71% and a net margin of 17.99%. The company’s revenue was up 11.0% on a year-over-year basis. During the same period last year, the business posted $1.05 EPS.
IDXX has been the topic of several recent research reports. Credit Suisse Group boosted their price objective on shares of IDEXX Laboratories from $282.00 to $293.00 and gave the company an “outperform” rating in a research note on Friday, August 16th. Goldman Sachs Group assumed coverage on shares of IDEXX Laboratories in a research note on Monday, September 9th. They issued a “neutral” rating and a $277.00 target price for the company. Guggenheim set a $310.00 target price on shares of IDEXX Laboratories and gave the company a “buy” rating in a report on Friday, November 1st. BidaskClub lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, October 24th. Finally, Zacks Investment Research cut shares of IDEXX Laboratories from a “hold” rating to a “sell” rating and set a $267.00 price target for the company. in a report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $289.57.
In related news, VP Giovani Twigge sold 14,750 shares of IDEXX Laboratories stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $250.51, for a total value of $3,695,022.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director M Anne Szostak sold 3,283 shares of the stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $279.37, for a total value of $917,171.71. Following the transaction, the director now directly owns 584 shares in the company, valued at approximately $163,152.08. The disclosure for this sale can be found here. Insiders have sold 116,130 shares of company stock worth $31,118,453 in the last ninety days. 2.70% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of IDXX. Altshuler Shaham Ltd acquired a new position in IDEXX Laboratories in the second quarter worth $28,000. Lenox Wealth Management Inc. acquired a new stake in shares of IDEXX Laboratories during the third quarter worth $31,000. Thor Advisors LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $34,000. Usca Ria LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $36,000. Finally, Institutional & Family Asset Management LLC lifted its position in shares of IDEXX Laboratories by 150.0% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 150 shares of the company’s stock worth $41,000 after buying an additional 90 shares during the last quarter. Institutional investors and hedge funds own 87.05% of the company’s stock.
Shares of NASDAQ IDXX traded down $0.49 during mid-day trading on Friday, hitting $251.37. 289,857 shares of the company were exchanged, compared to its average volume of 527,816. The stock has a 50 day simple moving average of $263.57 and a 200-day simple moving average of $270.95. IDEXX Laboratories has a 1-year low of $176.11 and a 1-year high of $294.57. The company has a quick ratio of 0.80, a current ratio of 1.12 and a debt-to-equity ratio of 3.76. The firm has a market cap of $21.61 billion, a price-to-earnings ratio of 59.01 and a beta of 0.72.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Article: Stock Split
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.